Published in final edited form as:

J Org Chem. 2008 October 17; 73(20): 8085–8088. doi:10.1021/jo801224j.

Synthesis of Enantiomerically Pure (S)-Methanocarbaribo Uracil Nucleoside Derivatives for Use as Antiviral Agents and P2Y Receptor Ligands

Artem Melman^{†,‡}, Minghong Zhong[§], Victor E. Marquez^{§,*}, and Kenneth A. Jacobson^{†,*}

[†]Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam NY 13699

[‡]Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892

[§]Laboratory of Medicinal Chemistry, Center for Cancer Research, NCI-Frederick, NIH, Frederick, MD 21702

Abstract

We have developed an approach toward enantiomerically pure (S)-methanocarba ribonucleosides based on several functional group transformations on a sensitive bicyclo[3.1.0]hexane system. D-Ribose was transformed into methanocarba alcohol **3** followed by conversion of the OH group to a nitrile with inversion of configuration at C4. The nitrile group was subsequently reduced in two stages to the 5'-hydroxymethyl group. An ester group appended to a tertiary carbon (C1) was transformed to an amino group as a nucleobase precursor.

Recent studies of the SAR of nucleosides and nucleotides as antiviral agents and receptor ligands have reported that conformational constraint of the ribose ring of such ligands allows the identification of preferred conformations of the normally freely-interconverting sugar ring. Use of the methanocarba, bicyclo[3.1.0]hexane ring system, which can be fixed in a North (N) or South (S) rigid envelope conformation,¹ as a ribose substitute has greatly aided these studies. For example, (S)-methanocarba-thymidine specifically inhibits the growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells without the toxicity of its North counterpart.² In the study of the GPCRs (G protein-coupled receptors) that respond to extracellular nucleosides (adenosine receptors) and nucleotides (P2Y receptors), the preference for a North (N) or South (S) ribose conformation depends on the receptor subtype.^{1,3,4,5} The P2Y₆ receptor for UDP prefers the (S)-methanocarba analogue of dUDP, which is more potent than the corresponding 2'-deoxyriboside, dUDP. This knowledge is now being used to design additional nucleotide analogues having enhanced potency and selectivity for a given receptor subtype. (N)-methanocarba analogues of 2'-deoxyadenosine 3',5'-bisphosphates constitute the most potent and selective antagonists of the P2Y₁ receptor, which have potential as antithrombotic agents.^{5,6}

Synthetic methods for methanocarba nucleosides have undergone refinement based on carbene cyclopropanation, metathesis, and other reactions.^{7,8,9,10} However, only the racemic form of (S)-methanocarba ribonucleosides has so far been reported.⁹ Our approach toward enantiomerically pure (S)-methanocarbanucleoside **1** (Scheme 1) was based on a previously published synthesis of (N)-methanocarba-based agonists of the A₃ adenosine receptor.¹¹ The synthesis of the North template started from L-ribose and involved as a key intermediate compound **2**. A closer look at its enantiomer **3** and the target (S)-methanocarba derivative **1** revealed a similar carbocyclic skeleton possessing an identical configuration of the two OH groups at positions 2 and 3. Enantiomer **3** can be therefore converted into the target (S)-methanocarbanucleotide **1** through: (a) replacement of the C4 hydroxyl with a CH₂OH group accompanied by inversion of configuration at C4; and (b) conversion of the ester group into a 2,4-pyrimidinedione ring.

Our initial synthetic plan (Scheme 1) involved conversion of alcohol **3** into alcohol **4** through substitution with a one-carbon nucleophile synthon. Subsequent transformations of alcohol **4** included converting the ester function into a primary amino group followed by final assembly of the uracil ring.

Preparation of alcohol **6** (Scheme 2) from D-ribose followed a published procedure for the synthesis of its enantiomer¹² and was accomplished in 6% overall yield.¹³ Subsequent acid-catalyzed rearrangement of alcohol **6** provided a 60:40 equilibrium mixture of alcohols **3** and **6** that could not be separated chromatographically. The equilibrium mixture was enriched to a ratio of 80:20 by the selective crystallization of alcohol **6**, leading to further enhancement to a ratio of 90:10 through recrystallization. The resultant mixture of alcohols **3** and **6** was converted into the corresponding triflates **7** and **8**, which could be separated chromatographically. However, due to instability of triflates **7** and **8** all subsequent experiments were done using the mixture without purification.

A first attempt at substitution with a one-carbon nucleophilic synthon involved reaction of triflate **8** with 2-lithio 1,3-dithiane (Scheme 2). Although triflate **8** was found to be unstable under the reaction conditions the nucleophilic substitution provided the desired dithiane **9** in 35% yield. The reaction proceeded with inversion of configuration at C4, as evidenced by a change in the coupling constants $J_{3,4}$ and $J_{4,5}$ from 6 Hz to zero in the ¹H NMR spectrum. Subsequent mercury perchlorate-assisted hydrolysis of dithiane **9** resulted in aldehyde **10** in low yield, most probably due to instability of the compound. Final reduction of aldehyde **10** with NaBH₄ provided target alcohol **4**.

Since the overall yield of alcohol **4** by this method was low, we tried an alternative one-carbon nucleophilic synthon. Nucleophilic substitution in triflate **8** with sodium cyanide (Scheme 2) provided the nitrile **11**, although in only 40% yield; however, replacement of sodium cyanide with lithium cyanide resulted in improved yield. Furthermore, we found that separation of triflates **8** and **7** was not necessary, and a 90:10 mixture of these isomers could be subjected to nucleophilic substitution to provide nitrile **11** as the only isomer in 63% yield.¹⁴

Our original synthetic plan involved hydrolysis of the ester group in nitrile **11** followed by a Curtius rearrangement. However, basic hydrolysis of nitrile **11** with NaOH in MeOH-H₂O (Scheme 3) resulted in formation of either ethyl 4-cyanobenzoate or 4-cyanobenzoic acid rather than the expected plain hydrolysis of the carboxylic group. The same outcome was observed with other reagents commonly used for basic hydrolysis, such as H₂O-Et₃N or K₂CO₃.

Since (N)-methanocarba derivatives are generally stable to bases, the observed transformation is undoubtedly related to the presence of an acidic proton at the α-position to the cyano group. The most probable mechanism of the rearrangement involves C4 deprotonation followed by ring-opening of the cyclopropane ring driven by the strain of the bicyclo[3.1.0]hexane system

and aromatization of the resultant carbanion through sequential β -eliminations to give ethyl 4-cyanobenzoate **14**.

We surmised that the undesired transformation could be avoided by decreasing the acidity of the α -proton at C4. This can be most easily accomplished through a reduction of the cyano group to obtain a CH_2OH group. However, reduction of the cyano group of the nitrile was complicated since complex hydrides that are most commonly used for such transformations are incompatible with the ester functionality of nitrile **11**. This problem was solved through the catalytic hydrogenation of nitrile **11** (Scheme 4). Although catalytic hydrogenation of nitriles is most commonly used for the preparation of amines,¹⁵ we found that the reaction could be stopped at the stage of aldehyde **10**. Conducting the hydrogenation in a $\text{MeOH-H}_2\text{O-AcOH}$ solution resulted in rapid hydrolysis of the initially formed imine **15**, thus preventing its further reduction. The resulting unstable aldehyde **10** was immediately reduced with NaBH_4 to yield alcohol **4** in 55% overall yield.

TBDPS protection of alcohol **4** produced silyl ether **16**, which was hydrolyzed into acid **17** (Scheme 4). Acid **17** was converted into the corresponding azide **18** through formation of a mixed anhydride followed by reaction with sodium azide. Thermal rearrangement of azide **18** was conducted in the presence of benzyl alcohol and resulted in the Cbz-protected amine **19**, which was deprotected by hydrogenation to afford amine **20** (Scheme 5).

Building of the uracil ring from amine **20** followed a previously described procedure for the syntheses of chiral 2'-deoxyribo versions of (S)-methanocarba-nucleosides.¹⁶ Reaction of the amine **20** with an 3-ethoxyacryloyl isocyanate¹⁶ afforded the urea **21** in 70% yield. Cyclization of **21** with ethanolic HCl resulted in the concomitant removal of the acetal and TBDPS protection of the hydroxyl groups, to yield the target (S)-methanocarba nucleoside **1** in 21% yield from compound **21**.

In conclusion, we have developed an approach toward enantiomerically pure (S)-methanocarba nucleosides based on functional group transformation on a sensitive bicyclo[3.1.0]hexane system. These derivatives are now suitable for detailed studies in biological systems.

Experimental Section

(1S,2S,5S,3R,4R)-1-Ethoxycarbonyl-4-cyano-2,3-O-isopropylidene-2,3-dihydroxybicyclo[3.1.0] hexane (**11**)

A solution of alcohol **3** (0.97 g, 4 mmol) and pyridine (0.35 g, 4.4 mmol) in CH_2Cl_2 (8.8 mL) at 0 °C was treated dropwise over a period of 2 min with a solution of trifluoromethanesulfonic anhydride (1.24 g, 4.4 mmol) in CH_2Cl_2 (8.8 mL). The reaction mixture was stirred at 0 °C for 10 min more after completing the addition, and hexane (25 mL) was added. After 5 min the resultant suspension was filtered through pad of silica gel and the silica gel was washed with 30% EtOAc-hexane mixture (100 mL). The combined organic filtrates were evaporated at room temperature, the resultant residue of the triflate was dissolved in dry CH_2Cl_2 (2 mL) at 0 °C, and 0.5 M solution of lithium cyanide in DMF (7.8 mL) was added to the solution. The reaction mixture was stirred at 0 °C for 30 min, dissolved in a 50% EtOAc-hexane mixture (50 mL), washed with water (2×10 mL) and brine (1×10 mL), dried (Na_2SO_4), and evaporated. The residue was purified by flash chromatography (10% to 20% EtOAc-hexane) to afford **11** as colorless oil (0.63 g, 2.5 mmol, 63%); $[\alpha]_{\text{D}}^{20} = -77.9^\circ$ ($c = 1.82$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 5.54 (d, 1H, $J = 6.9$ Hz), 4.90 (d, 1H, $J = 6.9$ Hz), 4.20 (m, 2H), 3.18 (s, 1H), 2.40 (dd, 1H, $J = 5.7, 9.6$ Hz), 1.67 (dd, 1H, $J = 5.4, 9.3$ Hz), 1.50 (s, 3H), 1.42 (t, 1H, $J = 5.4$ Hz), 1.30 (s, 3H), 1.29 (t, 3H, $J = 7.2$ Hz); ^{13}C NMR (75 MHz, CDCl_3): 170.9, 119.1, 112.9, 85.7, 80.7, 61.5, 35.6, 34.8, 26.0, 24.2, 19.3, 14.2.

(1S,2S,5S,3R,4R)-1-Ethoxycarbonyl-2,3-O-isopropylidene-2,3-dihydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexanecarboxylate (4)

Method A. A solution of nitrile **11** (0.25 g, 1 mmol) in MeOH (3 mL), H₂O (1.5 mL), and HOAc (0.5 mL) was treated with 10% Pd/C (20 mg). The flask was filled with hydrogen and stirred for 2 h at room temperature. The mixture of unreacted nitrile **11** and aldehyde **10** was filtered, and the filtrate was evaporated at room temperature. The residue was dissolved in EtOAc (30 mL), washed with satd. NaHCO₃-H₂O solution until CO₂ evolution ceased, dried (Na₂SO₄), and evaporated at room temperature. The residue was purified by flash chromatography (20% to 30% EtOAc-hexane) to afford the crude aldehyde, which was dissolved in MeOH (5 mL) and treated with NaBH₄ (20 mg, 0.5 mmol), followed by acetone (1 mL) after 10 min.). The reaction mixture was evaporated and the residue was dissolved in EtOAc (20 mL), washed with brine (3 mL), dried (Na₂SO₄), and evaporated. The residue is purified by flash chromatography (20 to 30% EtOAc-hexane) to afford the title compound as colorless oil (0.14 g, 0.55 mmol, 55%). [α]_D²⁰ = -18.35° (c = 0.60, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.36 (d, 1H, *J* = 6.6 Hz), 4.59 (d, 1H, *J* = 6.9 Hz), 4.15 (m, 2H), 3.66 (br. m, 2H), 2.37 (t, 1H, *J* = 6.0 Hz), 1.99 (dd, 1H, *J* = 6.0, 9.3 Hz), 1.49 (s, 3H), 1.42 (t, 1H, *J* = 5.2 Hz), 1.29 (s, 3H), 1.25 (t, 3H, *J* = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 172.8, 110.0, 85.0, 80.5, 64.6, 60.9, 46.8, 37.6, 35.5, 26.2, 24.1, 19.6, 14.2.

(1S,2S,5S,3R,4R)-1-Ethoxycarbonyl-4-[(tert-butyldiphenylsilyloxy)methyl]-2,3-O-isopropylidene-2,3-dihydroxybicyclo[3.1.0]hexane (16)

To a stirred solution of alcohol **4** (0.80 g, 3.1 mmol) and imidazole (0.10 g, 1.5 mmol) in DMF (3 mL) was added neat *tert*-butyldiphenylchlorosilane (1.26 g, 4.5 mmol) followed by the dropwise addition of triethylamine (0.81 g, 8 mmol). The reaction mixture was stirred for 14 h at room temperature diluted with 20% EtOAc-hexane (50 mL), washed with water (2 $\times$ 20 mL), brine, dried (Na₂SO₄), and evaporated. The residue was purified by flash chromatography (0% to 20% EtOAc-hexane) to give silyl ether **16** as colorless oil (1.05 g, 2.1 mmol, 69%); [α]_D²⁰ = -45.8° (c = 0.98, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.64 (m, 4H), 7.42 (m, 6H), 5.37 (d, 1H, *J* = 7.2 Hz), 4.57 (d, 1H, *J* = 7.2 Hz), 4.13 (m, 2H), 3.65 (br. m, 2H), 2.35 (t, 1H, *J* = 4.8 Hz), 2.07 (dd, 1H, *J* = 6.0, 9.6 Hz), 1.50 (s, 3H), 1.41 (t, 1H, *J* = 5.1 Hz), 1.29 (s, 3H), 1.24 (t, 3H, *J* = 7.2 Hz), 1.05 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 172.9, 135.7, 133.1, 129.9, 127.8, 110.9, 85.5, 80.9, 65.9, 60.9, 46.7, 38.1, 36.2, 26.9, 26.3, 24.2, 19.9, 19.2, 14.3.

(1S,2S,5S,3R,4R)-4-[(tert-butyldiphenylsilyloxy)methyl]-2,3-O-isopropylidene-2,3-dihydroxybicyclo[3.1.0]hexane-1-carboxylic acid (17)

A solution of silyl ether **16** (1.0 g, 2 mmol) in methanol (50 mL) was treated with 6 M NaOH (4 mL) and stirred under reflux for 2 h, evaporated, neutralized with conc. HCl, and extracted with CH₂Cl₂ (3 $\times$ 30 mL). The combined organic extracts were dried (Na₂SO₄), evaporated, and the residue was purified by flash chromatography (10% to 50% EtOAc-hexane) to afford **17** as colorless oil (0.71 g, 1.5 mmol, 76%); [α]_D²⁰ = -51.5° (c = 0.80, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.62 (m, 4H), 7.39 (m, 6H), 5.32 (d, 1H, *J* = 7.2 Hz), 4.53 (d, 1H, *J* = 7.2 Hz), 3.65 (br. m, 2H), 2.38 (t, 1H, *J* = 4.8 Hz), 2.15 (m, 1H), 1.60 (m, 1H), 1.50 (s, 3H), 1.29 (s, 3H), 1.27 (t, 3H, *J* = 7.2 Hz), 1.05 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 179.8, 135.7, 133.1, 129.9, 127.9, 111.1, 85.2, 80.4, 65.8, 46.8, 37.8, 36.9, 26.9, 26.3, 24.2, 20.7, 19.2.

(1S,2S,5S,3R,4R)-1-azidocarbonyl-4-[(tert-butyldiphenylsilyloxy)methyl]-2,3-O-isopropylidene-2,3-dihydroxybicyclo[3.1.0]hexane (18)

A solution of acid **17** (0.70 g, 1.5 mmol) and *N,N*-diisopropylethylamine (0.20 g, 1.6 mmol) in acetone (15 mL) at room temperature was treated with neat diphenylchlorophosphate (0.43 g, 1.6 mmol). The reaction mixture was stirred for 30 min followed by treatment with aqueous sodium azide (0.13 g in 2 mL, 2 mmol). The reaction mixture was stirred for 30 min, evaporated

at room temperature, and the residue was partitioned between water (10 mL) and CH₂Cl₂ (50 mL). The organic layer was dried (Na₂SO₄), evaporated, and the residue was purified by flash chromatography (10 to 30% EtOAc-hexane) to afford the title compound as colorless oil (0.67 g, 0.13 mmol, 88%); $[\alpha]_D^{20} = -63.0^\circ$ (c = 0.48, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.63 (m, 4H), 7.35 (m, 6H), 5.21 (d, 1H, *J* = 6.3 Hz), 4.45 (d, 1H, *J* = 7.2 Hz), 3.59 (d, 2H, *J* = 4.2 Hz), 2.29 (t, 1H, *J* = 4.2 Hz), 2.10 (m, 1H), 1.56 (m, 1H), 1.50 (m, 1H), 1.41 (s, 3H), 1.20 (s, 3H), 0.99 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 179.4, 135.7, 133.1, 130.0, 127.9, 111.2, 85.4, 80.4, 65.8, 46.2, 41.1, 38.3, 26.9, 26.3, 24.2, 21.9, 19.3.

***N*-{[(1*S*,2*S*,5*S*,3*R*,4*R*)-1-benzoyloxycarbamino-4-[(*tert*-butyldiphenylsilyloxy)methyl]-2,3-*O*-isopropylidene-2,3-dihydroxybicyclo[3.1.0]hexane (19)}**

A solution of azidoketone **18** (0.67 g, 1.3 mmol) and benzyl alcohol (1 mL) in toluene (20 mL) was refluxed for 5 h. The reaction mixture was evaporated, the residue was twice purified by flash chromatography (5% methanol-chloroform, then 30% EtOAc-hexane) to afford title compound as colorless oil (0.54 g, 1.1 mmol, 69%); $[\alpha]_D^{20} = -24.7^\circ$ (c = 1.08, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.78 (br. d, 4H), 7.37 (m, 11H), 5.32 (br. s, 1H), 5.18 (br. s, 2H), 5.05 (br. d, 1H, *J* = 5 Hz), 4.57 (br. d, 1H, *J* = 6 Hz), 3.97 (br. s, 2H), 2.42 (br. t, 1H, *J* = 6.6 Hz), 1.72 (m, 1H), 1.60 (s, 3H), 1.29 (s, 3H), 1.43 (s, 3H), 1.19 (s, 9H), 1.08 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 159.1, 156.2, 136.6, 135.8, 135.7, 129.8, 127.9, 128.2, 128.6, 133.8, 111.0, 84.1, 83.4, 66.6, 65.3, 47.7, 46.0, 31.4, 27.0, 26.3, 24.2, 19.4, 17.7.

[(1*S*,2*S*,5*S*,3*R*,4*R*)-1-Amino-4-[(*t*-butyldiphenylsilyloxy) methyl]-2,3-*O*-isopropylidene-2,3-dihydroxybicyclo[3.1.0] hexane (20)

A solution of benzyl carbamate **19** (0.63 g, 1.1 mmol) in methanol (5 mL) was stirred under hydrogen in the presence of 10% Pd on carbon (50 mg) for 2 h at atmospheric pressure. The reaction mixture was filtered and the residue was evaporated to afford title compound as colorless oil (0.42 g, 0.96 mmol, 87%); $[\alpha]_D^{20} = -22.9^\circ$ (c = 0.68, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.66 (m, 4H), 7.42 (m, 6H), 4.68 (d, 1H, *J* = 7.5 Hz), 4.48 (d, 1H, *J* = 7.5 Hz), 3.68 (m, 2H, *J* = 4.2 Hz), 2.17 (t, 1H, *J* = 4.2 Hz), 1.6 (m, 1H), 1.49 (s, 3H), 1.36 (m, 1H), 1.25 (s, 3H), 1.09 (s, 9H), 0.97 (t, 1H, *J* = 4.2 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 135.7, 133.4, 129.9, 127.8, 88.5, 84.7, 66.4, 48.5, 47.0, 32.0, 27.1, 26.9, 26.4, 24.4, 19.4, 18.1.

[(1*S*,2*S*,3*R*,4*R*)-1-(3-Ethoxyacryloyl)aminocarbamoyl-4-[(*tert*-butyldiphenylsilyloxy)-2,3-*O*-isopropylidene-2,3-dihydroxybicyclo[3.1.0]hexane (21)

To a solution of 3-ethoxyacrylic acid (2 mmol) in CH₂Cl₂ (1 mL) was added neat oxalyl chloride (2 mmol) and DMF (0.02 g). The reaction mixture was stirred for 30 min, and was evaporated at room temperature. The residue was dissolved in toluene (5 mL) and stirred with silver cyanate (4 mmol) for 4 h. The resultant solution was filtered, and a 1.25 mL aliquot of the solution was evaporated for reaction with amine **20**. The evaporated aliquot was dissolved in CH₂Cl₂ (2 mL) and added to a precooled (-78 °C) solution of amine **20** (0.20 g, 0.46 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 14 h. The reaction mixture was evaporated and the residue was purified by flash chromatography to afford the title urea as pale yellow oil (0.20 g, 0.34 mmol, 74%); $[\alpha]_D^{20} = -32.7^\circ$ (c = 0.44, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H), 8.92 (s, 1H), 7.66 (m, 4H), 7.57 (d, 1H, *J* = 12.0 Hz), 7.36 (m, 6H), 5.16 (d, 1H, *J* = 12 Hz), 5.05 (d, 1H, *J* = 7.2 Hz), 4.43 (d, 1H, *J* = 7.2 Hz), 3.82 (m, 4H), 2.34 (t, 1H, *J* = 7.8 Hz), 1.67 (dd, 1H, *J* = 4.8, 9.0 Hz), 1.50 (s, 3H), 1.23 (m, 7H), 1.05 (s, 9H); ¹³C (75 MHz, CDCl₃) δ 167.4, 163.0, 155.1, 135.6, 133.8, 129.7, 127.7, 110.9, 97.8, 83.8, 83.5, 67.6, 65.3, 47.9, 45.2, 31.4, 27.0, 26.3, 24.1, 19.4, 17.4, 14.5.

1-[(1*S*,2*S*,5*S*,3*R*,4*R*)-2,3-Dihydroxy-4-(hydroxymethyl) bicyclo[3.1.0]hexyl]-1,3-dihydropyrimidine-2,4-dione (1)

A solution of urea **21** (0.20 g, 0.34 mmol) in ethanol (3 mL) was added conc. HCl (0.1 mL). The reaction mixture was refluxed for 5 h, and evaporated. The residue was purified by flash chromatography (0 to 20% MeOH-chloroform) to afford compound as amorphous solid (18 mg, 0.071 mmol, 21%); $[\alpha]_D^{20} = -51.6$ ($c = 0.64$, MeOH). ^1H NMR (300 MHz, CD_3OD) δ 7.50 (d, 1H, $J = 7.5$ Hz), 5.59 (d, 1H, $J = 8.1$ Hz), 4.43 (d, 1H, $J = 6.6$ Hz), 3.83 (d, 1H, $J = 6.6$ Hz), 3.60 (m, 2H), 2.07 (t, 1H, $J = 4.8$ Hz), 1.60-1.70-1 (m, 2H), 0.90 (m, 1H); ^{13}C NMR (75 MHz, CD_3OD) δ 184.9, 151.1, 105.3, 78.8, 76.0, 67.7, 56.2, 54.3, 29.4, 18.5, 13.5.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Dr. Dina M. Sigano for optical rotation measurements and Drs. James A. Kelley, Christopher Lai, and Dilip Tosh for high resolution mass spectral measurements. This research was supported in part by the Intramural Research Programs of the National Institutes of Health, NIDDK and the Center for Cancer Research, National Cancer Institute at Frederick.

References

1. Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, Matteucci MD. *J Med Chem* 1996;39:3739–3747. [PubMed: 8809162]
2. Schelling P, Claus MT, Johnert R, Marquez VE, Schulz GE, Scapozza L. *J Biol Chem* 2004;279:32832–32838. [PubMed: 15163659]
3. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmström M, Boyer JL, Harden TK, Jacobson KA. *J Med Chem* 2002;45:208–218. [PubMed: 11754592]
4. Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa M, Marquez VE, Harden TK, Jacobson KA. *J Med Chem* 2005;48:8108–8111. [PubMed: 16366591]
5. Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, Jacobson KA. *J Med Chem* 2003;46:4974–4987. [PubMed: 14584948]
6. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA, Gachet C. *J Pharm Exp Therap* 2006;316:556–563.
7. Lee K, Cass C, Jacobson KA. *Org Lett* 2001;3:597–599. [PubMed: 11178834]
8. Gallos JK, Koftis TV, Massen ZS, Dellios CC, Mourtzinis IT, Coutouli-Argyropoulou E, Koumbis AE. *Tetrahedron* 2002;58:8043–8053.
9. Shin KJ, Moon HR, George C, Marquez VE. *J Org Chem* 2000;65:2172–2178. [PubMed: 10774042]
10. Lee JA, Kim HO, Tosh DK, Moon HR, Kim S, Jeong LS. *Org Lett* 2006;8:5081–5083. [PubMed: 17048848]
11. (a) Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA. *J Med Chem* 2005;48:1745–1758. [PubMed: 15771421] (b) Joshi BV, Moon HR, Fetting JC, Marquez VE, Jacobson KA. *J Org Chem* 2005;70:439–447. [PubMed: 15651784]
12. Joshi BV, Melman A, Mackman RL, Jacobson KA. *Nucleosides, Nucleotides, and Nucleic Acids* 2007 2008;27:279–291.
13. All intermediate compounds possessed spectral data identical to the published ones in ref. 12.
14. Triflate **7** presumably does not produce the corresponding nitrile.
15. Hudlicky, M. *Reductions in Organic Chemistry*. Washington, D.C.: American Chemical Society; 1984. p. 239-240.
16. Ezzitouni A, Marquez VE. *J Chem Soc, Perkin Trans* 1997;1:1073–1078.

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 4.

Scheme 5.